The aims of this study were to (i) evaluate the analytical performance of the Lumipulse G β-Amyloid 1-42, β-Amyloid 1-40, total Tau, and pTau 181 assays on the fully automated LUMIPULSE G600II platform; (ii) compare CSF biomarker results of the Lumipulse G assays with the established manual ELISA assays (INNOTEST® β-AMYLOID(1-42), INNOTEST β-AMYLOID(1-40), INNOTEST hTAU Ag, and INNOTEST PHOSPHO-TAU(181P)); and (iii) establish cut-offs and the clinical performance of the Lumipulse G assays for AD diagnosis. This evidence concerns the gene MAPT and Alzheimer disease.